肝细胞肝癌免疫治疗研究进展

Advances in immunotherapy of hepatocellular carcinoma

肝细胞肝癌(HCC)是我国常见的消化道恶性肿瘤之一。晚期HCC预后较差,化疗和索拉非尼治疗有效率不高。越来越多的研究表明,机体免疫功能状态与HCC的发生和进展有着密切关系。近年来,肿瘤免疫治疗已成为研究热点,其通过诱导特异性抗肿瘤免疫效应,延长患者的生存时间,应经成为HCC综合治疗的重要组成部分。本文就HCC的免疫治疗临床研究进展进行综述。

Hepatocellular carcinoma （HCC） is one of the common digestive tract malignant tumors in China. The prognosis of advanced HCC is poor and the curative effect of chemotherapy and sorafenib is disappointing. A growing number of studies have shown that there is close relationship between patients＇ immune status and the development of HCC. In recent years, immunotherapy has become one of hot spots in cancer research. By inducing specific anti-tumor immune response, it can prolong the survival time of HCC patients, which has become an integral part of HCC comprehensive treatment. We reviewed the current progress of immunotherapy for HCC.